Friday, July 4, 2025 7/4/2025

Basic Investigation and Translational Applications Concerning the Cell and Molecular Biology of Blood and Vascular Cells

Award Number: R35HL139937
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 03/01/2018
PERIOD OF PERFORMANCE END DATE: 02/28/2026

Group Awards By:

View Award Description

Basic Investigation and Translational Applications Concerning the Cell and Molecular Biology of Blood and Vascular Cells - Studies proposed in this application encompass and extend long-standing interests of the Principal Investigator in the cell and molecular biology of blood and vascular cells. The proposed Program is comprised of two ambitious, impactful projects designed to fill important conceptual gaps in their respective fields, and that have long been judged to be of interest and relevance to the overall mission of the NHLBI; namely (1) The role of PECAM-1 in vascular cell function, and (2) The pathophysiology of neonatal alloimmune thrombocytopenia (NAIT). PECAM-1 (also known as CD31) is a cellular adhesion and signaling receptor that functions in circulating blood cells to limit the rate and extent of cellular activation. PECAM-1 is also the most highly-expressed component of the endothelial cell-cell junction, where it functions as a homophilic adhesive stress-response protein to maintain endothelial cell junctional integrity and speed restoration of the vascular permeability barrier following inflammatory or thrombotic challenge. We will exploit our recent determination of the three-dimensional structure of the PECAM-1 homophilic binding domain, our development of innovative PECAM-1-targeted tools and animal models, and our discovery that PECAM-1 is subject to conformational affinity modulation to examine the potential for PECAM-1 to serve as a novel therapeutic target for a wide range of vascular permeability disorders, including sepsis-induced vascular leakage and ischemia-reperfusion injury. This Program will also focus on developing new tools, models and treatments for NAIT – a rare, but catastrophic, clinically important bleeding disorder caused by maternal antibodies generated in response to paternally-inherited antigens present on fetal platelets that re-cross the placenta and bind to fetal and/or neonatal platelets, resulting in thrombocytopenia often serious enough to require transfusion, and in the most severe cases causing intracranial hemorrhage and intrauterine death. Despite advances in treatment, NAIT remains the leading cause of intracranial hemorrhage in full-term infants, often leading to lifelong disability. We propose to combine recent transformative advances in CRISPR gene editing technology with the ability to generate megakaryocyte progenitor cells, megakaryocytes, and platelets from induced pluripotent stem cells to establish a transformative diagnostic platform designed to narrow the existing “diagnostic gap” to improve treatment and care of NAIT - namely the creation of platelet alloantigen-specific cell lines capable of long-term self-renewal, cryopreservation, and distribution; thereby providing a potentially inexhaustible source of iPS-derived platelets for diagnostic, investigative, (and potentially future therapeutic) use. CRISPR technology has also allowed us to develop a novel humanized mouse model of NAIT that will allow us to resolve a series of outstanding issues in platelet alloimmunity. Taken together, this research program will apply cutting-edge technology to lay the groundwork for continuing advances in the diagnosis and treatment of these and related blood and vascular disorders of relevance to the mission of the National Heart, Lung and Blood Institute.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2024	VERSITI WISCONSIN, INC.	638 N 18TH ST	MILWAUKEE	WI	53233	MILWAUKEE	USA	Blood Diseases and Resources Research	000	7	11/12/2024	NON-COMPETING CONTINUATION	$0
2025	2024	VERSITI WISCONSIN, INC.	638 N 18TH ST	MILWAUKEE	WI	53233	MILWAUKEE	USA	Blood Diseases and Resources Research	001	7	3/17/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $966,838 )
2024	2024	VERSITI WISCONSIN, INC.	638 N 18TH ST	MILWAUKEE	WI	53233	MILWAUKEE	USA	Blood Diseases and Resources Research	001	7	6/12/2024	NON-COMPETING CONTINUATION	$78,926
2024	2024	VERSITI WISCONSIN, INC.	638 N 18TH ST	MILWAUKEE	WI	53233	MILWAUKEE	USA	Blood Diseases and Resources Research	002	7	8/30/2024	NON-COMPETING CONTINUATION	$0
2024	2024	VERSITI WISCONSIN, INC.	638 N 18TH ST	MILWAUKEE	WI	53233	MILWAUKEE	USA	Blood Diseases and Resources Research	000	7	3/4/2024	NON-COMPETING CONTINUATION	$887,912
2024	2023	VERSITI WISCONSIN, INC.	638 N 18TH ST	MILWAUKEE	WI	53233	MILWAUKEE	USA	Blood Diseases and Resources Research	003	6	9/9/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $966,838

Issue Date FY: 2023 ( Subtotal = $986,569 )
2023	2023	VERSITI WISCONSIN, INC.	638 N 18TH ST	MILWAUKEE	WI	53233	MILWAUKEE	USA	Blood Diseases and Resources Research	000	6	4/21/2023	NON-COMPETING CONTINUATION	$986,569
2023	2023	VERSITI WISCONSIN, INC.	638 N 18TH ST	MILWAUKEE	WI	53233	MILWAUKEE	USA	Blood Diseases and Resources Research	001	6	5/22/2023	NON-COMPETING CONTINUATION	$0
														Subtotal = $986,569

Issue Date FY: 2022 ( Subtotal = $986,569 )
2022	2022	VERSITI WISCONSIN, INC.	638 N 18TH ST	MILWAUKEE	WI	53233	MILWAUKEE	USA	Blood Diseases and Resources Research	001	5	6/8/2022	NON-COMPETING CONTINUATION	$98,659
2022	2022	VERSITI WISCONSIN, INC.	638 N 18TH ST	MILWAUKEE	WI	53233	MILWAUKEE	USA	Blood Diseases and Resources Research	000	5	3/16/2022	NON-COMPETING CONTINUATION	$887,910
														Subtotal = $986,569

Issue Date FY: 2021 ( Subtotal = $986,569 )
2021	2021	VERSITI WISCONSIN, INC.	638 N 18TH ST	MILWAUKEE	WI	53233	MILWAUKEE	USA	Blood Diseases and Resources Research	000	4	3/19/2021	NON-COMPETING CONTINUATION	$986,569
														Subtotal = $986,569

Issue Date FY: 2020 ( Subtotal = $986,569 )
2020	2020	VERSITI WISCONSIN, INC.	638 N 18TH ST	MILWAUKEE	WI	53233	MILWAUKEE	USA	Blood Diseases and Resources Research	000	3	2/25/2020	NON-COMPETING CONTINUATION	$986,569
														Subtotal = $986,569

Issue Date FY: 2019 ( Subtotal = $986,569 )
2019	2019	VERSITI WISCONSIN, INC.	638 N 18TH ST	MILWAUKEE	WI	53233	MILWAUKEE	USA	Blood Diseases and Resources Research	000	2	2/21/2019	NON-COMPETING CONTINUATION	$986,569
														Subtotal = $986,569

Issue Date FY: 2018 ( Subtotal = $986,967 )
2018	2018	BLOODCENTER OF WISCONSIN, INC.	638 N 18TH ST	MILWAUKEE	WI	53233	MILWAUKEE	USA	Blood Diseases and Resources Research	000	1	1/26/2018	NEW	$986,967
														Subtotal = $986,967

Grand Total All Awards = $6,886,650

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Basic Investigation and Translational Applications Concerning the Cell and Molecular Biology of Blood and Vascular Cells

Award Number: R35HL139937

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 03/01/2018

PERIOD OF PERFORMANCE END DATE: 02/28/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer